ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

October 27, 2026

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Performance

52-Week Range 32.2% below 52-week high

20.99

18.3952W Low 30.9652W High

1 Week 0.1% below 1-week high

20.001W Low 21.011W High

ACADIA Pharmaceuticals Inc. - Common Stock (ACAD) traded between $18.39 and $30.96 over the past 52 weeks and last traded at $20.99, 32.2% below its 52-week high. Over the past week it ranged between $20.00 and $21.01.

Past 12 Months

+3.3%

+4.4%

-22.7%

-6.1%

-20.2%

-6.2%

1W +$0.67

1M +$0.88

3M -$6.16

6M -$1.36

YTD -$5.30

1Y -$1.38

ACAD was -6.2% over the past year, -6.1% over six months, -20.2% year to date, +3.3% in the last week.

12 Months vs Market

ACAD

-6.2%

DIA

+11.8%

SPY

+12.4%

QQQ

+9.1%

IWM

+16.4%

Over the past 12 months ACAD returned -6.2% versus DIA (Dow) +11.8%, SPY (S&P 500) +12.4%, QQQ (Nasdaq 100) +9.1% and IWM (Russell 2000) +16.4%.

Volume & Liquidity 0.11× 3-mo avg

Today 209,669 3-mo avg 1.9M

1.6M

1.9M

1.7M

YTD

1.7M

ACAD most recently traded 209,669 shares against a 3-month average daily volume of 1.9M.

More News

October 21, 2026

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

October 21, 2026

From FN Media

ACADIA Pharmaceuticals (NASDAQ:ACAD) Displays High Growth Momentum and a Breakout Setup ↗

August 31, 2026

Via Chartmill

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

October 21, 2026

Via FinancialNewsMedia

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

October 20, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

October 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

October 06, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance ↗

August 04, 2026

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

September 29, 2026

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

September 28, 2026

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial ↗

September 24, 2026

Via MarketBeat

September 24, 2026

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

August 24, 2026

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data ↗

August 12, 2026

Via MarketBeat

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Via The Motley Fool

ACADIA Pharmaceuticals Q2 Earnings Call Highlights ↗

August 04, 2026

Via MarketBeat

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 04, 2026

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference

July 30, 2026

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

July 20, 2026

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

July 15, 2026

An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? ↗

July 11, 2026

Via The Motley Fool

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

July 06, 2026